Trial Profile
A Phase II, Non-comparative, Open Label, Multi-center Study of Sunitinib in Patients With Metastatic or Recurrent Thymic Carcinoma
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 28 Jan 2019
Price :
$35
*
At a glance
- Drugs Sunitinib (Primary)
- Indications Malignant thymoma
- Focus Therapeutic Use
- Acronyms KOSMIC
- 18 Jan 2019 Status changed from active, no longer recruiting to completed.
- 26 Sep 2018 Results evaluating efficacy of sunitinib after chemotherapy were presented at the 19th World Conference on Lung Cancer.
- 25 Apr 2017 Planned End Date changed from 1 Oct 2017 to 1 Apr 2018.